Grifols Stock News

There could be a downside to the consensus revenue and margins of Grifols <> (GIKLY) (GIFLF), JPMorgan analyst James D Gordon warned, issuing the firm’s earnings preview for…

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Alla

The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreover, developments in terms of technology is expected to positively impact the growth of the market during the forecast period. Also, rise in number of blood related disorders is further expected to bolster the growth of market over the next few years.

Grifols, S.A. (NASDAQ:GRFS)s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $10.86, but opened at $10.41. Grifols shares last traded at $10.39, with a volume of 5,349 shares traded. A number of research firms recently commented on GRFS. Citigroup raised Grifols from a neutral rating to []

DUBLIN--(BUSINESS WIRE)--The "Global Bleeding Disorder Treatment Market (2021-2026) by Type, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Bleeding Disorder Treatment Market is estimated to be USD 13.5 Bn in 2021 and is expected to reach USD 18.6 Bn by 2026, growing at a CAGR of 10%. The factors driving the growth of the bleeding disorder treatment market a

Crossmark Global Holdings Inc. purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 755,784 shares of the biotechnology companys stock, valued at approximately $11,042,000. Crossmark Global Holdings Inc. owned []

Grifols, S.A. (NASDAQ:GRFS)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $10.21 and last traded at $10.28, with a volume of 32985 shares trading hands. The stock had previously closed at $10.51. GRFS has been the topic of several recent research reports. Citigroup raised […]

Key Prominent Players Covered in the Plasma Fractionation Market Research Report Are CSL (U.S.) , Grifols, S.A(Spain) , Baxter (U.S.) , Kedrion S.p.A (Italy) , Octapharma (Switzerland) , Shire- Part of Takeda Pharmaceutical Company Limited (U.S.) , Biotest AG (Germany) , LFB (France) Key Prominent Players Covered in the Plasma Fractionation Market Research Report Are CSL (U.S.) , Grifols, S.A(Spain) , Baxter (U.S.) , Kedrion S.p.A (Italy) , Octapharma (Switzerland) , Shire- Part of Takeda Pharmaceutical Company Limited (U.S.) , Biotest AG (Germany) , LFB (France)

Global Nucleic Acid Amplification Market Synopsis: It gets easy to make informed decisions that eventually provide maximum ROI from the marketing expenditures with the winning Nucleic Acid Amplification Market report. A well-equipped global delivery center and highly-competent research team leads to

The report on the global Immunoglobulin market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that

Subcutaneous Immunoglobulin is used for treatment of primary immunodeficiency diseases, secondary immunodeficiency diseases, and others. Subcutaneous immunoglobulins are efficacious, well-tolerated, have a favorable safety profile, and are suitable for all patients where clinically appropriate. Subcutaneous immunoglobulins are preferred to intravenous

Plasma Protein Products Market 2021 this report is including with the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. Also, Plasma Protein Products Market (By major key players, By Types, By Applications, and Leading Regions)

Grifols S.A. (NASDAQ:GRFS) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.13% to the previous days close as strong demand from buyers drove the stock to $10.91. Actively observing the price movement in the last trading, the stock closed the session at $11.50, falling within a range of $10.86 and Grifols S.A. (NASDAQ: GRFS) Stock Price Forecast: $100 Read More »